Thermo Fisher recently celebrated the opening of its new Cell and Gene Therapy (CGT) Vision Centre in South Korea. The centre is part of the company's growing global network dedicated to supporting its customers and accelerating the development of personalised treatments.
“The CGT field is driving breakthroughs in treating rare and intractable diseases, advancing personalised medicine and shaping the future of regenerative medicine,” said Thermo Fisher’s Soo Jin Seok. “These innovations require highly specialised support from discovery through commercialisation. With the launch of the CGT Vision Centre, we will empower our customers with access to cutting-edge technologies, regulatory expertise and end-to-end workflow solutions – strengthening their ability to innovate and scale.”
According to market reports, South Korea cell and gene therapy market size is expected to record a CAGR of 16.9% during 2023-2027 to reach $1.067 billion by 2027, increasing from $0.489 billion in 2023. Over the last five years, the sector has recorded a CAGR of 21.2% to reach $0.403 billion in 2022.
